Search Within

Joachim Yahalom

  1. "Alison Moskowitz"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (22)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (56)
  2. Department of Medicine (56)
  3. Hematologic Malignancies, Division of (56)
  4. Lymphoma (56)
  5. Radiation Oncology, Department of (56)
  6. Survivorship Research (56)

More Groups

People
  1. Alison Moskowitz (56)
  2. Andrew Zelenetz (44)
  3. Steven Horwitz (44)
  4. Paul Hamlin (39)
  5. Ariela Noy (38)
  6. David Straus (37)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (7)
  4. 2022 (3)
  5. 2021 (6)
  6. 2020 (7)

More Years

Publications
  1. Blood (24)
  2. Hematological Oncology (8)
  3. Journal of Clinical Oncology (5)
  4. Blood Advances (3)
  5. British Journal of Haematology (3)
  6. Blood Cancer Journal (2)

More Publications

Publishers
  1. American Society of Hematology (27)
  2. Wiley Blackwell (8)
  3. American Society of Clinical Oncology (5)
  4. Elsevier Inc. (5)
  5. John Wiley & Sons (3)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (56)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Treatment of vulvar mycosis fungoides tumors with localized radiotherapy
    Journal Article

    Geller, S.; Pitter, K.; Moskowitz, A.; Horwitz, S. M.; Yahalom, J.; Myskowski, P. L.
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save
  • Early toxicities associated with radiation based conditioning for relapsed/refractory Hodgkin lymphoma patients undergoing high dose therapy and autologous stem cell transplantation (HDT-ASCT)
    Meeting Abstract

    Shah, G. L.; Scordo, M.; Devlin, S. M.; Yahalom, J.; Matasar, M. J.; Moskowitz, A.; Giralt, S. A.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 years of experience
    Journal Article

    Rimner, A.; Lovie, S.; Hsu, M.; Chelius, M.; Zhang, Z.; Chau, K.; Moskowitz, A. J.; Matasar, M.; Moskowitz, C. H.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save